TWI838736B - 做為腺苷A2a受體拮抗劑之化合物及包含該化合物之醫藥組合物 - Google Patents

做為腺苷A2a受體拮抗劑之化合物及包含該化合物之醫藥組合物 Download PDF

Info

Publication number
TWI838736B
TWI838736B TW111115277A TW111115277A TWI838736B TW I838736 B TWI838736 B TW I838736B TW 111115277 A TW111115277 A TW 111115277A TW 111115277 A TW111115277 A TW 111115277A TW I838736 B TWI838736 B TW I838736B
Authority
TW
Taiwan
Prior art keywords
compound
amino
triazolo
furan
trioxan
Prior art date
Application number
TW111115277A
Other languages
English (en)
Chinese (zh)
Other versions
TW202302593A (zh
Inventor
李昌植
李載元
李在英
朴藝松
郭達容
炫進 金
Original Assignee
韓商鐘根堂股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 韓商鐘根堂股份有限公司 filed Critical 韓商鐘根堂股份有限公司
Publication of TW202302593A publication Critical patent/TW202302593A/zh
Application granted granted Critical
Publication of TWI838736B publication Critical patent/TWI838736B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW111115277A 2021-04-23 2022-04-21 做為腺苷A2a受體拮抗劑之化合物及包含該化合物之醫藥組合物 TWI838736B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2021-0053352 2021-04-23
KR20210053352 2021-04-23

Publications (2)

Publication Number Publication Date
TW202302593A TW202302593A (zh) 2023-01-16
TWI838736B true TWI838736B (zh) 2024-04-11

Family

ID=83722733

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111115277A TWI838736B (zh) 2021-04-23 2022-04-21 做為腺苷A2a受體拮抗劑之化合物及包含該化合物之醫藥組合物

Country Status (11)

Country Link
US (1) US20240217978A1 (https=)
EP (1) EP4326724A4 (https=)
JP (1) JP7646873B2 (https=)
KR (1) KR102863028B1 (https=)
CN (1) CN117120443A (https=)
AU (1) AU2022262777C1 (https=)
BR (1) BR112023021918A2 (https=)
CA (1) CA3207935A1 (https=)
MX (1) MX2023012338A (https=)
TW (1) TWI838736B (https=)
WO (1) WO2022224180A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023296161A1 (en) * 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688581A (zh) * 2001-11-30 2005-10-26 先灵公司 [1,2,4]-三唑二环腺苷A2a受体拮抗剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0459702A1 (en) * 1990-05-29 1991-12-04 Zeneca Limited Azole Derivatives
US5356894A (en) 1990-05-29 1994-10-18 Rodney Peter W Morpholinyl substituted [1,2,4]-triazolo[1,5-a]triazine as antagonist
CA2148502A1 (en) * 1993-09-06 1995-03-16 Fumio Suzuki Antidepressants
US6232297B1 (en) * 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6664252B2 (en) * 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
CA2459304A1 (en) * 2001-09-13 2003-03-20 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
JPWO2003068776A1 (ja) * 2002-02-15 2005-06-02 協和醗酵工業株式会社 [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
WO2004092173A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
EP3810610A1 (en) * 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
JP7197206B2 (ja) * 2018-06-26 2022-12-27 チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド A2a受容体拮抗薬として用いられるトリアゾロトリアジン誘導体
AU2019383948A1 (en) * 2018-11-20 2021-05-20 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CN112028891B (zh) * 2019-07-30 2022-07-05 厦门宝太生物科技股份有限公司 腺苷受体拮抗剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1688581A (zh) * 2001-11-30 2005-10-26 先灵公司 [1,2,4]-三唑二环腺苷A2a受体拮抗剂

Also Published As

Publication number Publication date
JP2024515739A (ja) 2024-04-10
JP7646873B2 (ja) 2025-03-17
KR102863028B1 (ko) 2025-09-22
AU2022262777C1 (en) 2025-02-13
WO2022224180A1 (en) 2022-10-27
TW202302593A (zh) 2023-01-16
BR112023021918A2 (pt) 2023-12-19
AU2022262777A1 (en) 2023-09-21
MX2023012338A (es) 2023-10-30
US20240217978A1 (en) 2024-07-04
CN117120443A (zh) 2023-11-24
AU2022262777B2 (en) 2024-11-07
EP4326724A4 (en) 2025-03-26
CA3207935A1 (en) 2022-10-27
EP4326724A1 (en) 2024-02-28
KR20220146348A (ko) 2022-11-01

Similar Documents

Publication Publication Date Title
EP4161935B1 (en) Brm targeting compounds and associated methods of use
CN113631557B (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
AU2021213258B2 (en) Compounds and uses thereof
EP3656782B1 (en) Peptide amide compound and preparation method and medical use thereof
CN109153665B (zh) 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN102711473B (zh) 布鲁顿酪氨酸激酶抑制剂
JP2025510656A (ja) 複素環式化合物、その組成物、及びそれらを用いた治療方法
CA3207392A1 (en) Cdk inhibitor
JP2018537501A (ja) 多環式tlr7/8アンタゴニスト及び免疫障害の治療におけるそれらの使用
US11332459B2 (en) Benzimidazole derivatives and their uses
CA2957048A1 (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
JP2021533125A (ja) Tlr7/8アンタゴニストおよびそれらの使用
CN103896946A (zh) 用于预防及治疗多种自身免疫疾病的新化合物
BR112020019963A2 (pt) Composto com atividade anticâncer
WO2023059583A1 (en) Heterobifunctional compounds and their use in treating disease
TWI838736B (zh) 做為腺苷A2a受體拮抗劑之化合物及包含該化合物之醫藥組合物
WO2024054954A1 (en) Heterobifunctional compounds and methods of treating disease
RU2840068C2 (ru) СОЕДИНЕНИЕ В КАЧЕСТВЕ АНТАГОНИСТА АДЕНОЗИНОВОГО РЕЦЕПТОРА A2a И СОДЕРЖАЩАЯ ЕГО ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2024054602A1 (en) Heterobifunctional compounds and methods of treating disease
KR20250006237A (ko) 축합 바이사이클릭 헤테로방향족 화합물 및 암의 치료에서의 이의 용도
RU2809763C2 (ru) Соединение, обладающее противораковой активностью
EA048707B1 (ru) Brm направленные соединения и связанные способы применения
HK40097855A (zh) 作为腺苷a2a受体拮抗剂的化合物及包含其的药物组合物
EA050840B1 (ru) Brm направленные соединения и связанные способы применения
TW202506681A (zh) Myc家族原癌基因蛋白之調節劑